

Yang Lin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4877022/publications.pdf>

Version: 2024-02-01

29
papers

215
citations

1170033

9
h-index

1255698

13
g-index

30
all docs

30
docs citations

30
times ranked

377
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of the prevalence and nature of potentially inappropriate medication use in geriatric outpatients between tertiary and community healthcare settings: a multicenter cross-sectional study. <i>International Journal of Clinical Pharmacy</i> , 2022, , .	1.0	2
2	Ticagrelor vs. Clopidogrel in Older Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights From a Real-World Registry. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 859962.	1.1	4
3	Metformin and the risk of neurodegenerative diseases in patients with diabetes: A meta-analysis of population-based cohort studies. <i>Diabetic Medicine</i> , 2022, 39, e14821.	1.2	5
4	Application and evaluation of sacubitril/valsartan in patients with cardiac insufficiency during perioperative period of cardiac surgery. <i>Experimental and Therapeutic Medicine</i> , 2022, 24, .	0.8	1
5	Danthron attenuates experimental atherosclerosis by targeting foam cell formation. <i>Experimental Physiology</i> , 2021, 106, 653-662.	0.9	5
6	Pharmacokinetics and Pharmacodynamics of Esomeprazole/Sodium Bicarbonate Immediate-Release Capsules in Healthy Chinese Volunteers: A Cross-Over, Randomized Controlled Trial. <i>Advances in Therapy</i> , 2021, 38, 1660-1676.	1.3	4
7	Convallatoxin Promotes M2 Macrophage Polarization to Attenuate Atherosclerosis Through PPAR γ -Integrin α 5 β 1 Signaling Pathway. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 803-812.	2.0	14
8	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPH3127: A Phase I, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Clinical Therapeutics</i> , 2021, 43, 735.e1-735.e14.	1.1	1
9	Personalized Antiplatelet Therapy Based on CYP2C19 Genotypes in Chinese ACS Patients Undergoing PCI: A Randomized Controlled Trial. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 676954.	1.1	4
10	Clopidogrel versus Ticagrelor in CYP2C19 Loss-of-Function Allele Noncarriers: A Real-World Study in China. <i>Thrombosis and Haemostasis</i> , 2021, , .	1.8	3
11	Distribution Analysis of Salvianolic Acids in Myocardial Ischemic Pig Tissues by Automated Liquid Extraction Surface Analysis Coupled with Tandem Mass Spectrometry. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-9.	0.5	1
12	Effect of ABCB1 3435C>T Genetic Polymorphism on Pharmacokinetic Variables of Tacrolimus in Adult Renal Transplant Recipients: A Systematic Review and Meta-analysis. <i>Clinical Therapeutics</i> , 2020, 42, 2049-2065.	1.1	11
13	Pharmacokinetics of Single and Multiple Doses of Omega-3 Carboxylic Acids in Healthy Chinese Subjects: A Phase I, Open-label Study. <i>Clinical Pharmacology in Drug Development</i> , 2020, 9, 985-994.	0.8	3
14	Towards low cost, multiplex clinical genotyping: 4-fluorescent Kompetitive Allele-Specific PCR and its application on pharmacogenetics. <i>PLoS ONE</i> , 2020, 15, e0230445.	1.1	7
15	New insights into the vancomycin-induced nephrotoxicity using in vitro metabolomics combined with physiologically based pharmacokinetic modeling. <i>Journal of Applied Toxicology</i> , 2020, 40, 897-907.	1.4	10
16	Impact of Implementing CYP2C19 Genotype-Guided Antiplatelet Therapy on P2Y12 Inhibitor Selection and Clinical Outcomes in Acute Coronary Syndrome Patients After Percutaneous Coronary Intervention: A Real-World Study in China. <i>Frontiers in Pharmacology</i> , 2020, 11, 582929.	1.6	13
17	Title is missing!. , 2020, 15, e0230445.		0
18	Title is missing!. , 2020, 15, e0230445.		0

#	ARTICLE	IF	CITATIONS
19	Title is missing!. , 2020, 15, e0230445.		0
20	Title is missing!. , 2020, 15, e0230445.		0
21	Both CYP2C19 and PON1 Q192R Genotypes Influence Platelet Response to Clopidogrel by Thrombelastography in Patients with Acute Coronary Syndrome. Cardiovascular Therapeutics, 2019, 2019, 1-8.	1.1	24
22	Time Course of the Effects of Buxin Yishen Decoction in Promoting Heart Function and Inhibiting the Progression of Renal Fibrosis in Myocardial Infarction Caused Type 2 Cardiorenal Syndrome Rats. Frontiers in Pharmacology, 2019, 10, 1267.	1.6	6
23	Serum metabolomics reveals the progression of coronary artery stenosis in patients with hypercholesterolemia. Blood Coagulation and Fibrinolysis, 2019, 30, 205-216.	0.5	1
24	Polymorphisms and pharmacogenomics for the toxicity of methotrexate monotherapy in patients with rheumatoid arthritis. Medicine (United States), 2017, 96, e6337.	0.4	33
25	Time-Course of the Effects of QSYQ in Promoting Heart Function in Ameroid Constrictor-Induced Myocardial Ischemia Pigs. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-13.	0.5	11
26	Pharmacokinetics of Pilsicainide Hydrochloride for Injection in Healthy Chinese Volunteers: A Randomized, Parallel-Group, Open-Label, Single-Dose Study. Clinical Therapeutics, 2014, 36, 255-263.	1.1	4
27	Time course label-free quantitative analysis of cardiac muscles of rats after myocardial infarction. Molecular BioSystems, 2014, 10, 505.	2.9	15
28	Plasma metabonomics study on Chinese medicine syndrome evolution of heart failure rats caused by LAD ligation. BMC Complementary and Alternative Medicine, 2014, 14, 232.	3.7	15
29	Simultaneous quantitative analysis of fasudil and its active metabolite in human plasma by liquid chromatography electro-spray tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2010, 52, 242-248.	1.4	18